financetom
CAL
financetom
/
Consumer Discretionary
/
CAL
All stocks News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Commodities
Caleres, Inc.CAL
USD
- At close
USD
- Until the end
The complete list of US stocks
1D
5D
1M
1Y
5Y
MAX
Overview >
% Change
Description >

Caleres, Inc. engages in the retail and wholesale of footwear business in the United States, Canada, Eastern Asia, and internationally.

It operates through Famous Footwear and Brand Portfolio segments. The company offers licensed, branded, and private-label athletic, casual, and dress footwear products.

The company provide brand name athletic, casual, and dress shoes, including Nike, Skechers, adidas, Vans, Crocs, Converse, Puma, Birkenstock, New Balance, Under Armour, Dr.

Martens, Asics, Timberland, Bearpaw, Skechers, HeyDude, Franco Sarto, Rykä, Vince, Bzees, Veronica Beard, and Zodiac brands, as well as company-owned and licensed brands, such as LifeStride, Dr.

Scholl's Shoes, Blowfish Malibu, and Naturalizer. The company also operates naturalizer.com, naturalizer.ca, vionicshoes.com, samedelman.com, allenedmonds.com, drschollsshoes.com, lifestride.com, francosarto.com, ryka.com, bzees.com, and zodiacshoes.com, as well as Vince.com, blowfishshoes.com, and veronicabeard.com websites.

In addition, it designs, sources, manufactures, and markets footwear to retail stores, such as online retailers, national chains, department stores, mass merchandisers, and independent retailers.

Further, the company wholesales men's apparel, leather goods, and accessories under the Allen Edmonds brand; footwear for women under LifeStride brand; Italian footwear Franco Sarto brand; athletic footwear for women under the Rykä brand; women's shoe collection under the Vince brand; and women's footwear under the Bzees brand; other footwear under Zodiac brand; and women's footwear collection under Veronica Beard brand, as well as Via Spiga brand.

The company was formerly known as Brown Shoe Company, Inc. and changed its name to Caleres, Inc. in May 2015.

The company was founded in 1878 and is headquartered in St. Louis, Missouri.

Latest News >
NHTSA to expand probe into 286,000 GM vehicles over possible engine failure issue
NHTSA to expand probe into 286,000 GM vehicles over possible engine failure issue
Oct 27, 2025
Oct 27 (Reuters) - The National Highway Traffic Safety Administration is expanding its probe into 286,000 GM vehicles in the U.S. over a possible engine failure issue, the safety regulator said on Monday. The NHTSA said the issue stems from engine bearing failures in GM's L87 6.2-litre engine installed in models such as the Chevrolet Silverado 1500 and Cadillac Escalade....
BRIEF-Sotherly Hotels To Be Acquired By Joint Venture Backed By Kemmons Wilson Hospitality Partners And Ascendant Capital Partners
BRIEF-Sotherly Hotels To Be Acquired By Joint Venture Backed By Kemmons Wilson Hospitality Partners And Ascendant Capital Partners
Oct 27, 2025
Oct 27 (Reuters) - Sotherly Hotels Inc ( SOHO ): * SOTHERLY HOTELS INC. ( SOHO ) TO BE ACQUIRED BY JOINT VENTURE BACKED BY KEMMONS WILSON HOSPITALITY PARTNERS AND ASCENDANT CAPITAL PARTNERS * SOTHERLY HOTELS INC ( SOHO ) - KW KINGFISHER TO BUY SOTHERLY SHARES FOR $2.25 PER SHARE * SOTHERLY HOTELS INC ( SOHO ) - APOLLO...
Keurig Dr Pepper Q3 Adjusted Earnings, Net Sales Rise
Keurig Dr Pepper Q3 Adjusted Earnings, Net Sales Rise
Oct 27, 2025
06:34 AM EDT, 10/27/2025 (MT Newswires) -- Keurig Dr Pepper ( KDP ) reported Q3 adjusted earnings Monday of $0.54 per diluted share, up from $0.51 a year earlier. Analysts polled by FactSet expected $0.54. Net sales for the quarter ended Sept. 30 were $4.31 billion, compared with $3.89 billion a year earlier. Analysts surveyed by FactSet expected $4.15 billion....
Novartis shares slip, Avidity soars after $12 billion biotech deal
Novartis shares slip, Avidity soars after $12 billion biotech deal
Oct 27, 2025
LONDON (Reuters) -Shares of Novartis fell 1% on Monday following news of the company's plans to acquire U.S. biotech Avidity Biosciences ( RNA ) for about $12 billion, marking the Swiss drugmaker's largest acquisition under CEO Vas Narasimhan. Before the Avidity deal, announced on Sunday, Novartis had already committed over $17 billion this year on acquisitions and licensing deals. They...
Copyright 2023-2026 - www.financetom.com All Rights Reserved